These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 15608976)

  • 1. Functional and motor response to low dose olanzapine in Huntington's disease: case report.
    Laks J; Rocha M; Capitão C; Domingues RC; Ladeia G; Lima M; Engelhardt E
    Arq Neuropsiquiatr; 2004 Dec; 62(4):1092-4. PubMed ID: 15608976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine in Huntington's disease.
    Paleacu D; Anca M; Giladi N
    Acta Neurol Scand; 2002 Jun; 105(6):441-4. PubMed ID: 12027832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose olanzapine in Huntington's disease.
    Bonelli RM; Niederwieser G; Tribl GG; Költringer P
    Int Clin Psychopharmacol; 2002 Mar; 17(2):91-3. PubMed ID: 11890191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine for Huntington's disease: an open label study.
    Bonelli RM; Mahnert FA; Niederwieser G
    Clin Neuropharmacol; 2002; 25(5):263-5. PubMed ID: 12410058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain SPECT imaging in Huntington's disease before and after therapy with olanzapine. Case report.
    Etchebehere EC; Lima MC; Passos W; Maciel Júnior JA; Santos AO; Ramos CD; Camargo EE
    Arq Neuropsiquiatr; 1999 Sep; 57(3B):863-6. PubMed ID: 10751925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Riluzole and olanzapine in Huntington's disease.
    Bonelli RM; Niederwieser G; Diez J; Költringer P
    Eur J Neurol; 2002 Mar; 9(2):183-4. PubMed ID: 11882065
    [No Abstract]   [Full Text] [Related]  

  • 7. Olanzapine and Huntington's disease.
    Bogelman G; Hirschmann S; Modai I
    J Clin Psychopharmacol; 2001 Apr; 21(2):245-6. PubMed ID: 11270928
    [No Abstract]   [Full Text] [Related]  

  • 8. Risperidone long-acting injection and Huntington's disease: case series with significant psychiatric and behavioural symptoms.
    Johnston TG
    Int Clin Psychopharmacol; 2011 Mar; 26(2):114-9. PubMed ID: 21119522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of olanzapine for movement disorder in Huntington's disease: a first case report.
    Dipple HC
    J Neurol Neurosurg Psychiatry; 1999 Jul; 67(1):123-4. PubMed ID: 10454874
    [No Abstract]   [Full Text] [Related]  

  • 10. Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease.
    Coppen EM; Roos RA
    Drugs; 2017 Jan; 77(1):29-46. PubMed ID: 27988871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aripiprazole in the treatment of olanzapine-resistant psychotic and motor symptoms of Huntington's disease.
    Oulis P; Mourikis I; Konstantakopoulos G; Papageorgiou SG; Kouzoupis AV
    J Neuropsychiatry Clin Neurosci; 2010; 22(3):352c.e4-352.e5. PubMed ID: 20686147
    [No Abstract]   [Full Text] [Related]  

  • 12. Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease.
    Duff K; Beglinger LJ; O'Rourke ME; Nopoulos P; Paulson HL; Paulsen JS
    Ann Clin Psychiatry; 2008; 20(1):1-3. PubMed ID: 18297579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term effects of olanzapine in Huntington disease.
    Squitieri F; Cannella M; Porcellini A; Brusa L; Simonelli M; Ruggieri S
    Neuropsychiatry Neuropsychol Behav Neurol; 2001 Jan; 14(1):69-72. PubMed ID: 11234911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zotepine in Huntington's disease.
    Bonelli RM; Niederwieser G; Lahousen T; Hofmann P
    Hum Psychopharmacol; 2003 Apr; 18(3):227-9. PubMed ID: 12672176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.
    de Yebenes JG; Landwehrmeyer B; Squitieri F; Reilmann R; Rosser A; Barker RA; Saft C; Magnet MK; Sword A; Rembratt A; Tedroff J;
    Lancet Neurol; 2011 Dec; 10(12):1049-57. PubMed ID: 22071279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease.
    Murman DL; Giordani B; Mellow AM; Johanns JR; Little RJ; Hariharan M; Foster NL
    Neurology; 1997 Jul; 49(1):153-61. PubMed ID: 9222184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Huntington's disease: a negative family history case report demonstrating reduction of psychiatric symptoms with olanzapine].
    Coelho VA; Beato RG; Prado PH; Cardoso FE; Lauar H
    Braz J Psychiatry; 2009 Jun; 31(2):186-8. PubMed ID: 19578696
    [No Abstract]   [Full Text] [Related]  

  • 18. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study.
    van Vugt JP; Siesling S; Vergeer M; van der Velde EA; Roos RA
    J Neurol Neurosurg Psychiatry; 1997 Jul; 63(1):35-9. PubMed ID: 9221965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of Huntington's disease with olanzapine and valproate.
    Grove VE; Quintanilla J; DeVaney GT
    N Engl J Med; 2000 Sep; 343(13):973-4. PubMed ID: 11012330
    [No Abstract]   [Full Text] [Related]  

  • 20. Examining Huntington's disease patient and informant concordance on frontally mediated behaviors.
    Hergert DC; Sanchez-Ramos J; Cimino CR
    J Clin Exp Neuropsychol; 2015; 37(9):981-7. PubMed ID: 26332177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.